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Abstract Dystroglycan is a receptor responsible for crucial
interactions between extracellular matrix and cytoplasmic space.
We provide the first evidence that dystroglycan is truncated. In
HC11 normal murine and the 184B5 non-tumorigenic mammary
human cell lines, the expected L-dystroglycan 43 kDa band was
found but human breast T47D, BT549, MCF7, colon HT29,
HCT116, SW620, prostate DU145 and cervical HeLa cancer
cells expressed an anomalous W31 kDa L-dystroglycan band.
K-Dystroglycan was udetectable in most of the cell lines in which
L-dystroglycan was found as a W31 kDa species. An anomalous
W31 kDa L-dystroglycan band was also observed in N-methyl-
N-nitrosurea-induced primary rat mammary tumours. Reverse
transcriptase polymerase chain reaction experiments confirmed
the absence of alternative splicing events and/or expression of
eventual dystroglycan isoforms. Using protein extraction proce-
dures at low- and high-ionic strength, we demonstrated that both
the 43 kDa and W31 kDa L-dystroglycan bands harbour their
transmembrane segment. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Dystroglycan is a transmembrane protein that binds extra-
cellular matrix proteins, proteoglycans and cytosolic proteins,
and is formed by two subunits, K-dystroglycan (extracellular)
and L-dystroglycan (transmembrane). The two subunits,
which form a tight non-covalent complex, are encoded by
the same gene. Dystroglycan is expressed in a wide variety
of tissues and has important functions during early embryo-
genesis, for the mechanical stabilisation of muscles and also
for bacterial and viral infections [1,2]. The highly and hetero-
geneously glycosylated cell surface-associated K-dystroglycan
has a size which ranges from 120 to 180 kDa, depending on
di¡erent amounts of glycosylation [3,4]. It was recently dem-
onstrated that the glycosylation pattern of K-dystroglycan
changes during embryogenesis [5]. On the contrary, L-dystro-
glycan was identi¢ed as a 43 kDa band, sometimes accompa-
nied by a W31 kDa band, which presumably originates from
proteolytic fragmentation and/or alterations in its glycosyla-
tion pattern [6^9]. K-Dystroglycan binds with high a⁄nity to
extracellular matrix proteins and proteoglycans as laminins,
agrin and perlecan [10^14], whereas the cytoplasmic tail of L-
dystroglycan is involved in several interactions with a number
of proteins (dystrophin and its isoforms, Grb2, rapsyn) [15^
17]. Dystroglycan has the role of connecting the extracellular
matrix network to the cytoskeleton [18] and is possibly in-
volved in the regulation of signalling pathways [19].
In the past years, several studies have analysed the role of
cell^matrix interactions at the onset and/or during develop-
ment of cancer [20,21]. In particular, human mammary gland
carcinoma cell lines represent a paradigmatic model system
for such analysis [22].
In the present study, we have investigated the expression
pattern of dystroglycan in a panel of both normal and cancer
cell lines. Our results indicate that dystroglycan is diminished
in size in malignant cell lines due to post-translational pro-
cessing events.
2. Materials and methods
2.1. Cell cultures and animals
The HC11 mouse mammary epithelial cell line was clonally derived
from a spontaneously immortalised mammary epithelial cell culture
originally established from a midterm pregnant BALB/c mouse [23]
and was grown and maintained in RPMI 1640 medium (RPMI; Gib-
co, Merelbette, Belgium) supplemented with 10% heat-inactivated foe-
tal bovine serum (Gibco). The immortalised non-tumorigenic human
mammary epithelial cell line 184B5 (a gift from M. Stampfer, Law-
rence Berkeley Laboratory, Berkeley, CA, USA) was grown in sup-
plemented MCDB 170 medium (Clonetics Corp., San Diego, CA,
USA) as described elsewhere [24]. All the other cell lines used for
this study were obtained from the American Type Culture Collection
(Rockville, MD, USA) and were cultured as recommended by the
supplier.
The source and housing of the animals used in this study have been
described previously [25]. Brie£y, mammary cancers were induced in
50-day-old virgin-female Sprague-Dawley rats with a single intrave-
nous injection of 50 mg N-methyl-N-nitrosurea (NMU) per kg body
weight via the jugular vein, as described [25]. A total of seven tumours
were analysed. They were all malignant tumours with a predominant
cystic papillary adenocarcinoma pattern.
2.2. Total protein extract
Two di¡erent lysis bu¡ers were used: (1) TX-100: 1% Triton X-100,
150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EGTA, 1 mM EDTA,
0.2 mM PMSF, 0.5% NP-40, 1 mM benzamidine, 25 Wg/ml leupeptin;
(2) 20 mM Tris^HCl, pH 7.5, 2 mM EGTA, 2 mM EDTA, 6 mM
L-mercaptoethanol supplemented with protease inhibitors, 0.1%
sodium dodecyl sulfate (SDS), 1% NP-40. Exponentially growing cul-
tures of the indicated cell line were collected and cell pellets were
resuspended in the lysis bu¡er. The incubation was performed on
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ice with an occasional agitation. The cell lysates were centrifuged for
15 min. The supernatant corresponds to the total cell lysate whose
concentration was determined by BCA protein assay (Pierce).
A rabbit cardiac muscle membrane extract, partially puri¢ed in
non-dissociating conditions using succinyl-wheat germ agglutinin
(sWGA) agarose (Vector), was used as a positive control for L-dys-
troglycan. Frozen rabbit heart was homogenised with Physcotron NS-
10 in the bu¡er A containing 0.5 M NaCl, 50 mM Tris^HCl pH 7.4,
1.5 mM benzamidine, 0.25 mM PMSF, 2.5 Wg/ml leupeptin, 2.5 Wg/ml
pepstatin A, 2.5 Wg/ml aprotinin, 1% digitonin. After centrifugation at
100 000Ug for 30 min at 4‡C, the supernatant was incubated over-
night at 4‡C with a 50% batch of sWGA agarose beads. The beads
were washed extensively with bu¡er B which had the same composi-
tion as bu¡er A, except for a reduced concentration of digitonin
(0.1%), and then eluted with 0.35 M N-acetyl-glucosamine.
For low-ionic strength extractions, a single cell pellet was incubated
and mechanically lysed in 20 mM HEPES/NaOH pH 7.4, 10 mM
Na4P2O7, 1 mM EDTA, 1 mM EGTA, 10 Wg/Wl leupeptin, 1 mM
PMSF, 1 mM NEM, 1 mM benzamidine. The lysate mixture was
separated in two di¡erent tubes and centrifuged (14 000UgU10
min, 4‡C) and the supernatant was collected. One pellet was resus-
pended in TX-100 lysis bu¡er for Western blot analysis, whereas the
other was resuspended in high-ionic strength conditions (1 M KCl,
5 mM phosphate-bu¡ered saline (PBS), 1 mM EDTA, 10 Wg/Wl leu-
peptin, 1 mM PMSF, 1 mM NEM, 1 mM benzamidine, pH 7.5^8).
After centrifugation, a new supernatant fraction was collected and
dialysed in 10 mm Tris^HCl pH 7.5. The pellet fraction was washed
using 20 mM HEPES/NaOH pH 7.4 and then resuspended in TX-100
lysis bu¡er. Supernatant and pellet fractions were analysed by SDS^
PAGE and Western blot.
2.3. Gel electrophoresis and Western blot
Mouse monoclonal antibodies NCL-43DAG (clone 8D5) raised
against the last C-terminal 15 amino acidic residues of the L-dystro-
glycan cytoplasmic domain from Novocastra (Newcastle-upon Tyne,
UK) were used to detect L-dystroglycan, whereas for detection of
K-dystroglycan a mouse monoclonal VIA4-1 was used (Upstate Bio-
technology, USA). Proteins present in the lysates were boiled for 3 min
at 90‡ C in sample bu¡er and subjected to SDS^PAGE electrophoresis
on 4^15% gels. For Western blot analysis proteins were electrophor-
etically transferred to a nitrocellulose membrane at 35 V overnight.
The nitrocellulose was blocked with 3% milk powder in Tris-bu¡ered
saline (TBS; 150 mM NaCl, 10 mM Tris^HCl bu¡er pH 7.4) for 2 h
and incubated for 1 h with the monoclonal antibody in use, diluted
1:25 in TBS containing 3% bovine serum albumin. After washing in
TBS containing 3% milk powder and 0.1% Tween 20, the blots were
incubated for 30 min with anti-mouse antibodies horseradish peroxi-
dase-conjugated (Pierce) diluted 1:5000 in the same bu¡er. After one
wash for 20 min in 3% milk powder T-PBS and several washes in T-
PBS without milk, the ¢lters were incubated with the detection solu-
tion of the luminol-based ECL system (Pierce). Fluorographies were
carried out at room temperature by exposing nitrocellulose sheets to
Kodak ¢lms.
2.4. Reverse transcription and polymerase chain reaction (RT-PCR)
Total RNA was isolated from pelleted cells using the Rneasy Mini
Kit (Qiagen), obtaining a yield of 30^40 Wg from 0.5^1U106 cells. The
concentration and purity of RNA was determined spectrophotometri-
cally measuring the A260nm/A280nm ratio. For cDNA synthesis, the
Enhanced Avian RT-PCR kit (Sigma) was used. Usually, W5 Wg of
total RNA was incubated in DEPC-treated water and 2.5 WM oligo-
dT, and preheated at 70‡C for 10 min, then the mixture was incubated
in the presence of Avian reverse transcriptase at 42‡C for 1 h follow-
ing the conditions recommended by the manufacturer. PCR reactions
contained 5 Wl from the cDNA reactions, 200 WM dNTPs, W0.4 WM
of each primer, 1URed-Taq polymerase bu¡er and 2.5 U of Red-Taq
DNA polymerase. PCR reactions (total volume 50 Wl) were performed
in a GeneAmp PCR System 2400 temperature cycler (Perkin Elmer),
starting with 2 min at 96‡C followed by 35 cycles of 96‡C for 30 s,
55‡C for 30 s and 72‡C for 1 min. Primers used were: DAGMH
(forward) 5P-GGAGAACCCAACCAGCGCCCAGAGC-3P ; DAG-
AH (reverse) 5P-CGGGTGATATTCTGCAGGGTGATGG-3P ;
DAGAB (forward) 5P-CCATCACCCTGCAGAATATCACCCG-3P ;
HP20 (reverse) 5P-GACCGGTATGGGGTCATGTT-3P. Agarose gel
electrophoresis was used to analyse the PCR experiments and DNA
products were identi¢ed for the presence of 0.5 Wg/ml ethidium bro-
mide. The DNA 1 kb Plus Ladder1 was purchased from Gibco and
the control primer set for human L-actin from Stratagene.
3. Results and discussion
SDS^PAGE Western blot experiments were carried out us-
ing a commercially available antibody (IgG) (clone 8D5,
mouse monoclonal from Novocastra Laboratories) directed
versus the last C-terminal 15 amino acids of L-dystroglycan.
In Fig. 1 is reported a schematic drawing of the dystroglycan
molecule showing the epitope under analysis.
As shown in Fig. 2A, L-dystroglycan was detected as the
common 43 kDa band in the HC11 normal mouse and in the
184B5 non-tumorigenic human mammary gland cell lines
whereas in the breast cancer cell lines (T47D, BT549,
MCF7) a band displaying a reduced molecular mass (W31
kDa) was also clearly detectable. Remarkably, in the MCF7
cell line, this band was the only one revealed by the anti-L-
dystroglycan antibody. In order to rule out the possibility of
artefacts due to the sample preparation, we have used two
di¡erent total protein extraction procedures (see Section 2),
and we have obtained similar results (data not shown). It is
noteworthy that a series of independent protein extraction-
blot experiments were carried out on each of the cell lines
under analysis, always obtaining the same band pattern. In
addition, single cell lysates were repeatedly used after many
cycles of freezing/thawing and gave similar results, thus indi-
cating that an eventual activation of proteases during sample
preparation is very unlikely.
We have also found the L-dystroglycan W31 kDa band in a
number of di¡erent cell lines from human colon (HT29,
HCT116 and SW620), prostate (DU145) and cervical
(HeLa) cancer (Fig. 2B), indicating that the phenomenon is
not restricted to breast cancer cells. Interestingly, using a
monoclonal anti-K-dystroglycan (VIA4-1) antibody, we were
unable to detect the K-dystroglycan in the MCF7 and DU145
cells that only expressed the aberrant W31 kDa band (Fig.
2C). The K-dystroglycan band was also undetectable in HT29
that expressed both the 43 and the W31 kDa L-dystroglycan
band (Fig. 2C), suggesting also in this case a dramatic alter-
ation of the entire dystroglycan complex. To further extend
our analysis, we also analysed the expression of L-dystrogly-
can in a series of seven NMU-induced rat mammary tumours
and found that most of them express the aberrant W31 kDa
band (Fig. 2D).
It is noteworthy that the VIA4-1 antibody recognises an K-
dystroglycan carbohydrate epitope. Therefore, we cannot rule
out the possibility that VIA4-1 antibody fails to recognise K-
dystroglycan in tumour cells due to an alteration of its glyco-
sylation pattern. To verify whether K-dystroglycan was re-
leased in the culture medium, we have carried out Western
blot analysis on 24 h conditioned media samples but we were
unable to detect any signal in both normal and tumour cells
despite the fact that we concentrated the media up to 100-fold
(data not shown).
In order to exclude the possibility that the abnormalities
detected in the dystroglycan molecule could depend on alter-
native splicing and/or expression of eventual dystroglycan iso-
forms, we carried out qualitative RT-PCR experiments using
total RNA extracted from most of the cell lines under analy-
sis. In Fig. 3A is reported a scheme of the human dystrogly-
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can cDNA sequence. Dystroglycan human gene has been se-
quenced and mapped to chromosome 3 and displays an un-
complicated structure, sharing a single intron within its 5P end
[26]. We used a RT-PCR approach to analyse a region that
covers the last part of the C-terminal region of K-dystroglycan
and almost the entire L-dystroglycan sequence in normal and
malignant mammary gland cells. As shown in Fig. 3A, two
di¡erent pairs of primers were used in order to amplify a
sequence of 485 bp (corresponding to the C-terminal region
of K-dystroglycan, next to the Gly-Ser653ÿ654 post-translation-
al proteolytic site) and a sequence of 731 bp (almost corre-
sponding to the whole sequence of L-dystroglycan). As re-
ported in Fig. 3B, a number of bands were obtained whose
size exactly matches the expected calculated lengths (see Fig.
3A) in the 184B5, MCF7 and DU145 cell lines. Using most of
the cell lines under analysis, similar results were obtained
(data not shown). These data indicate that the W31 kDa L-
dystroglycan protein does not originate by alternative RNA
processing and/or expression of isoforms.
Malignant cell lines frequently overexpress proteases [27],
especially membrane-associated metalloproteases [28^30], that
are responsible for the extracellular matrix degradation, facil-
itating tumour invasiveness. It is possible that one of these
proteases provokes (or enhances) the degradation of L-dystro-
Fig. 1. Schematic drawing of dystroglycan. The dystroglycan portions recognised by the antibodies used for Western blot experiments are de-
picted. The mouse monoclonal VIA4-1 recognises a carbohydrate epitope belonging to K-dystroglycan. The 8D5 mouse monoclonal recognises
the very last 15 amino acids (P15) belonging to the C-terminus of L-dystroglycan.
Fig. 2. Western blot analysis. A: L-Dystroglycan is recognised by the monoclonal antibody 8D5 (see Fig. 1). Unless indicated, all the experi-
ments refer to human cell lines. The bands at 43 and W31 kDa are indicated by arrows. An intermediate band is also present in BT549 carci-
noma cell line. B: L-Dystroglycan is recognised by the monoclonal antibody 8D5 (see Fig. 1). The bands at 43 and W31 kDa are indicated by
arrows. C: K-Dystroglycan and L-dystroglycan are recognised by mouse monoclonal antibodies VIA4-1 and 8D5, respectively (see Fig. 1). Mo-
lecular mass marker at 200 kDa as well as the bands at 43 and W31 kDa are indicated by arrows. The nitrocellulose membrane was ¢rst incu-
bated with anti-K-dystroglycan and after with anti-L-dystroglycan antibody. D: L-Dystroglycan is recognised by the monoclonal antibody 8D5
(see Fig. 1). The bands at 43 and W31 kDa are indicated by arrows. Numbers from 1 to 7 show a series of NMU-induced rat mammary tu-
mours.
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glycan. If this would be the case, the breakdown should take
place at the N-terminus of L-dystroglycan [7], since the 8D5
antibody recognises a C-terminal epitope of the molecule (see
Fig. 1). A proteolytic process involving the removal of a cer-
tain amount of the N-terminal portion of L-dystroglycan
might a¡ect the interaction between K- and L-dystroglycan.
In fact, we have recently demonstrated by recombinant ex-
pression and solid-phase binding assays that this region is
able to bind with high a⁄nity and independently from glyco-
sylation to the C-terminal region of K-dystroglycan [31]. Our
observation that the K-dystroglycan is not detectable in the
cell lines (i.e. MCF7 and DU145, see Fig. 2C) that only ex-
press the L-dystroglycan W31 kDa band is consistent with
this hypothesis (see above).
Loss of a large portion of the N-terminus of the L-dystro-
glycan molecule might also compromise its targeting into the
cell membrane. To verify this possibility, we have carried out
protein extraction experiments at low-ionic strength (in 20
mM HEPES, pH 7.4, in the absence of any detergent, see
Section 2) which allow to separate cytoskeletal and mem-
brane-bound from cytosolic proteins. We found that the L-
dystroglycan bands were present in the membrane-bound
fraction of the BT549 cell line (Fig. 4). In addition, we were
not able to resolubilise the W31 kDa L-dystroglycan band
using KCl as expected for a cytoskeleton-associated protein
(Fig. 4). Thus, all the protein bands detected by the 8D5 anti-
body harbour their transmembrane segment, supporting the
hypothesis that L-dystroglycan undergoes a proteolytic cleav-
age within its N-terminal extracellular region that does not
a¡ect its targeting into the cell membrane. The alternative
possibility that the proteolysis could take place at the level
of the cytosolic region, and that the W31 kDa protein would
be recovered in the insoluble fraction because of its associa-
tion to cytoskeletal proteins, is challenged not only by the
experimental results reported in Fig. 4 but also by the notion
that the entire L-dystroglycan cytoplasmic tail has a calculated
molecular mass of about W13.5 kDa. It is unlikely that a
putative protein fragment of this size would show such an
anomalous electrophoretic behaviour accounting for a W31
kDa molecular mass. In order to collect conclusive evidences
on the hypothesis of a proteolytic breakdown, taking place
within the L-dystroglycan extracellular region will be neces-
sary to purify the W31 kDa peptide and unambiguously iden-
tify its N-terminal amino acids. In fact, it cannot be com-
pletely ruled out that the reduction of L-dystroglycan size
we observed might originate by a reduction (or lack) of the
carbohydrate epitopes modifying its extracellular region [6,7].
The decrease or absence of glycosylation may directly reduce
the molecular mass of L-dystroglycan. However, the hypoth-
esis that the W31 kDa band would originate by a signi¢cant
reduction of L-dystroglycan glycosylation is challenged by the
following considerations. In the extracellular region of human
dystroglycan there is only one N-linked glycosylation site
(Asn661). Recent experiments by Campbell’s laboratory, in
which tunicamycin and PNGaseF were employed, show that
N-linked glycosylation of L-dystroglycan accounts only for
W5 kDa [37]. Two candidate O-linked glycosylation sites
are also present, Ser729 and Thr734 (based on the NetOGlyc
program analysis available at the ExPASy server, Geneva,
Switzerland), but there are not direct evidences indicating
the presence (and the eventual size) of O-linked carbohydrate
molecules. It should also be noted that in two genetic variants
of the C2 muscle cell line, S26 and S27 which show a defect in
glycosaminoglycan biosynthesis, no alteration of Torpedo cali-
fornica L-dystroglycan electrophoretic mobility was detected
[38]. Last but not least, the anomalous electrophoretic behav-
iour of L-dystroglycan recombinant protein fragments [28^32]
strongly suggests that the di¡erence between the calculated
(26.4 kDa) and apparent molecular mass (43 kDa) of L-dys-
troglycan does not depend only on the presence of its carbo-
hydrate fraction. [28]. Taken together, these results indicate
Fig. 3. RT-PCR analysis. A: Scheme of the human dystroglycan
cDNA sequence. The primers used and the size of the ampli¢ed
portions, matching coding derived sequence (CDS) portions belong-
ing to K- and L-dystroglycan, are reported. B: 1% Agarose gel
showing DNA bands originating from PCR ampli¢cation experi-
ments referring to di¡erent cell lines. Control bands (661 bp) ob-
tained using human L-actin primers are also included.
Fig. 4. Western blot of protein extracts at low- and high-ionic
strength. BT549 human breast cancer cell extracts: pellet and super-
natant fractions were analysed using anti-L-dystroglycan antibody.
Pellet 1 was resuspended in TX-100 lysis bu¡er for Western blot
analysis. A separate pellet was washed and resuspended in high-
ionic conditions. Pellet 2, originating from high-ionic strength ex-
traction, was also resuspended in TX-100 lysis bu¡er (see Section
2). The bands at 43 and W31 kDa are indicated by arrows, an in-
termediate band is also present (see Fig. 2A).
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that the reduction of L-dystroglycan molecular mass (W31
kDa) is very unlikely to depend (at least entirely) on altered
glycosylation, thus favouring the hypothesis of a protease-
mediated cleavage.
Interactions between cell surface receptors and extracellular
matrix binding partners play crucial roles starting from early
morphogenesis as well as during adulthood [33^35]. In partic-
ular, the gene disruption experiment has revealed a crucial
role for dystroglycan since mouse development was arrested
as early as day 6.5 [36]. Also during tumorigenesis a critical
role has been assigned to the interactions between the cells
and the surrounding matrix. For example, the expression of
several integrin receptors is altered in malignant cells as com-
pared to their normal counterparts [21], and integrins have
been reported to play an important role for cell growth and
metastasis of several human tumours [20^22]. In this context,
the ¢nding that dystroglycan is present in an altered form in
several carcinoma cell lines is relevant. A reduction (or abol-
ishment) of dystroglycan function could in£uence the forma-
tion of strong contacts between basement membranes and the
cytoskeleton of cells [18], thus eventually favouring tumour
development and invasiveness. It is also of interest that L-
dystroglycan has been reported to bind to the growth fac-
tor-associated adaptor protein Grb2 [16] and recently, it was
demonstrated that the focal adhesion kinase p125FAK in brain
synaptosomes is associated to the dystrophin^glycoprotein
complex [19]. The alteration of dystroglycan found in carci-
noma cell lines might have dramatic consequences on signal
transduction and consequently on the metabolism and growth
rate of tumorigenic cells.
It was recently reported that in several cell lines (CHO, RT4
schwannoma and bovine aortic endothelial) a certain fraction
of K-dystroglycan is recovered as soluble in the culture me-
dium [37]. As already mentioned, degradation of the extracel-
lular region of L-dystroglycan would liberate K-dystroglycan
from its membrane-bound location. Our data may suggest
that K-dystroglycan is indeed not found at its normal mem-
brane-associated location in some of the carcinoma cell lines
which were analysed (Fig. 2C). The interaction between K-
and L-dystroglycan is supposed to have a high a⁄nity, and
in vitro a medium^high a⁄nity Kd of about 10 WM was esti-
mated [31]. However, other factors, like the presence of sta-
bilising proteins (for example members of the sarcoglycan
family), in£uence the stability of the dystroglycan complex
in epithelial cells [31,38].
The present data provide evidence that dystroglycan can be
processed in an aberrant fashion in several carcinoma cell
lines belonging to di¡erent tissues. Further experiments will
be necessary to verify whether abnormalities within dystrogly-
can processing mechanisms play a speci¢c role during carcino-
genesis in vivo and might have clinically relevant implications.
Acknowledgements: We gratefully acknowledge Ju«rgen Engel (Basel),
Markus A. Ruegg (Basel) and John L. Muschler (Berkeley) for useful
suggestions and critical reading of the manuscript and Mr. Pietro
Quirini (Rome) for his technical assistance.
References
[1] Henry, M.D. and Campbell, K.P. (1996) Curr. Opin. Cell Biol. 8,
625^631.
[2] Henry, M.D. and Campbell, K.P. (1999) Curr. Opin. Cell Biol.
11, 602^607.
[3] Ibraghimov-Beskrovnaya, O., Ervasti, J.M., Leveille, C.J.,
Slaughter, C.A., Sernett, S.W. and Campbell, K.P. (1992) Nature
355, 696^702.
[4] Ervasti, J.M., Burwell, A.L. and Geissler, A.L. (1997) J. Biol.
Chem. 272, 22315^22321.
[5] Leschziner, A., Moukhles, H., Lindenbaum, M., Gee, S.H., But-
terworth, J., Campbell, K.P. and Carbonetto, S. (2000) J. Neuro-
chem. 74, 70^80.
[6] Yamada, H., Chiba, A., Endo, T., Kobata, A., Anderson,
L.V.B., Hori, H., Fukuta-Ohi, H., Kanazawa, I., Campbell,
K.P., Shimizu, T. and Matsumura, K. (1996) J. Neurochem.
66, 1518^1524.
[7] Durbeej, M., Henry, M.D., Ferletta, M., Campbell, K.P. and
Ekblom, P. (1998) J. Histochem. Cytochem. 46, 449^457.
[8] Durbeej, M. and Campbell, K.P. (1999) J. Biol. Chem. 10,
26609^26616.
[9] Saito, F., Masaki, T., Kamakura, K., Anderson, L.V.B., Fujita,
S., Fukuta-Ohi, H., Sunada, Y., Shimizu, T. and Matsumura, K.
(1999) J. Biol. Chem. 274, 8240^8246.
[10] Gee, S.H., Blacher, R.W., Douville, P.J., Provost, P.R., Yurch-
enco, P.D. and Carbonetto, S. (1993) J. Biol. Chem. 268, 14972^
14980.
[11] Pall, E.A., Bolton, K.M. and Ervasti, J.M. (1996) J. Biol. Chem.
271, 3817^3821.
[12] McDearmon, E.L., Burwell, A.L., Combs, A.C., Renley, B.A., Sda-
no, M.T. and Ervasti, J.M. (1998) J. Biol. Chem. 273, 24139^24144.
[13] Gesemann, M., Brancaccio, A., Schumacher, B. and Ruegg,
M.A. (1998) J. Biol. Chem. 273, 600^605.
[14] Friedrich, M.V.K., Gohring, W., Morgelin, M., Brancaccio, A.,
David, G. and Timpl, R. (1999) J. Mol. Biol. 294, 259^270.
[15] Jung, D., Yang, B., Meyer, J., Chamberlain, J.S. and Campbell,
K.P. (1995) J. Biol. Chem. 270, 27305^27310.
[16] Yang, B., Jung, D., Motto, D., Meyer, J., Koretzky, G. and
Campbell, K.P. (1995) J. Biol. Chem. 270, 11711^11714.
[17] Cartaud, A., Coutant, S., Petrucci, T.C. and Cartaud, J. (1998)
J. Biol. Chem. 273, 11321^11326.
[18] Ervasti, J.M. and Campbell, K.P. (1993) J. Cell Biol. 122, 809^
823.
[19] Cavaldesi, M., Macchia, G., Barca, S., De¢lippi, P., Tarone, G.
and Petrucci, T.C. (1999) J. Neurochem. 72, 1648^1655.
[20] Schwartz, M.A. (1993) Cancer Res. 53, 1503^1506.
[21] Giancotti, F.G. and Mainiero, F. (1994) Biochim. Biophys. Acta
1198, 47^64.
[22] Zutter, M.M., Mazoujian, G. and Santoro, S.A. (1990) Am. J.
Pathol. 137, 863^870.
[23] Ball, R.K., Friis, R.R., Schoenenberger, C.A., Doppler, W. and
Groner, B. (1998) EMBO J. 7, 2089^2095.
[24] Stampfer, M.R. and Bartley, J.C. (1985) Proc. Natl. Acad. Sci.
USA 82, 2394^2398.
[25] Sgambato, A., Han, E.K.H., Zhang, Y.J., Moon, R.C., Santella,
R.M. and Weinstein, I.B. (1995) Carcinogenesis 16, 2193^2198.
[26] Ibraghimov-Beskrovnaya, O., Milatovich, A., Ozcelik, T., Yang,
B., Koepnick, K., Francke, U. and Campbell, K.P. (1993) Hum.
Mol. Genet. 2, 1651^1657.
[27] Garbett, E.A., Reed, M.W., Stephenson, T.J. and Brown, N.J.
(2000) Mol. Pathol. 53, 99^106.
[28] Vassalli, J.-D. and Pepper, M.S. (1994) Nature 370, 14^15.
[29] Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yama-
moto, E. and Seiki, M. (1994) Nature 370, 61^65.
[30] Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson,
W. and Quaranta, V. (1997) Science 277, 225^228.
[31] Di Stasio, E., Sciandra, F., Maras, B., Di Tommaso, F., Petrucci,
T.C., Giardina, B. and Brancaccio, A. (1999) Biochem. Biophys.
Res. Commun. 266, 274^278.
[32] Rosa, G., Ceccarini, M., Cavaldesi, M., Zini, M. and Petrucci,
T.C. (1996) Biochem. Biophys. Res. Commun. 223, 272^277.
[33] Rosen, G., Sanes, J.R., LaChance, R., Cunningham, J.M., Ro-
man, J. and Dean, D.C. (1992) Cell 69, 1107^1119.
[34] Ekblom, P. (1996) Curr. Opin. Cell Biol. 8, 700^706.
[35] Martin, P.T., Kaufman, S.J., Kramer, R.H. and Sanes, J.R.
(1996) Dev. Biol. 174, 125^139.
[36] Williamson, R.A., Henry, M.D., Daniels, K.J., Hrstka, R.F.,
Lee, J.C., Sunada, Y., Ibraghimov-Beskrovnaya, O. and Camp-
bell, K.P. (1997) Hum. Mol. Genet. 6, 831^841.
[37] Holt, K.H., Crosbie, R.H., Venzke, D.P. and Campbell, K.P.
(2000) FEBS Lett. 468, 79^83.
[38] Sugiyama, J., Bowen, D.C. and Hall, Z.W. (1994) Neuron 13,
103^115.
FEBS 24261 6-11-00
C. Losasso et al./FEBS Letters 484 (2000) 194^198198
